RecruitingPhase 2NCT07365462

Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1065890 in Adult Participants With Tardive Dyskinesia

Sponsor

Neurocrine Biosciences

Enrollment

100 participants

Start Date

Feb 6, 2026

Study Type

INTERVENTIONAL

Conditions

Tardive Dyskinesia

Summary

The primary objective of this study is to evaluate the efficacy of NBI-1065890 compared with placebo for the treatment of tardive dyskinesia (TD) in adult participants.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called NBI-1065890 and a drug called Placebo for people with tardive dyskinesia. The study is currently recruiting participants at 18 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNBI-1065890

Oral administration

DRUGPlacebo

Oral administration

Locations(18)

Neurocrine Clinical Site

Bryant, Arkansas, United States

Neurocrine Clinical Site

Chino, California, United States

Neurocrine Clinical Site

Fountain Valley, California, United States

Neurocrine Clinical Site

Huntington Beach, California, United States

Neurocrine Clinical Site

Long Beach, California, United States

Neurocrine Clinical Site

Temecula, California, United States

Neurocrine Clinical Site

Torrance, California, United States

Neurocrine Clinical Site

Boca Raton, Florida, United States

Neurocrine Clinical Site

Bonita Springs, Florida, United States

Neurocrine Clinical Site

Hialeah, Florida, United States

Neurocrine Clinical Site

Miami, Florida, United States

Neurocrine Clinical Site

Orange City, Florida, United States

Neurocrine Clinical Site

Tampa, Florida, United States

Neurocrine Clinical Site

Marietta, Georgia, United States

Neurocrine Clinical Site

Lincoln, Nebraska, United States

Neurocrine Clinical Site

Beachwood, Ohio, United States

Neurocrine Clinical Site

Fort Worth, Texas, United States

Neurocrine Clinical Site

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07365462

Related Trials

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

NCT0710511122 locations

Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities

NCT069971981 location

Single-Center, Double-Blind, Randomized, Placebo-Controlled Study on Efficacy and Safety of rTMS (With Precise Localization) in Relieving Motor Symptoms of TD

NCT071739201 location

Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates

NCT034950241 location